Why the study?
Does omecamtiv mecarbil improve myocardial contractility and clinical outcomes in patients with heart failure?
Does omecamtiv mecarbil improve myocardial contractility and clinical outcomes in patients with heart failure?
Omecamtiv mecarbil is a novel cardiac myosin activator that improves myocardial contractility through an innovative mechanism, offering a promising new therapeutic approach for heart failure.
May support myosin activation in acute HF; leaves open efficacy and safety in unstable patients pending randomized data.
Heart failure is a worldwide leading cause of hospital admissions. There is a critical need for new methods of management in acute heart failure. The current drug panel available in the treatment of hemodinamically unstable patients is not only limited, but it is also associated with deleterious side effects. Discoveries in the heart failure field seemed to lack an adequate answer and a change in paradigm may be necessary. The cardiac myosin activator omecamtiv mecarbil is a new therapeutic approach that improves the myocardial contractility through an innovative mechanism, avoiding the harmful effects of currently used inotropic agents. Several studies provided us with promising results, but further scientific proofs are needed.
No takes yet. Share an insight, caveat, or question.
Andrei et al. (2014) conducted a review in Heart failure. Omecamtiv mecarbil was evaluated.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: